Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DUK-CPG-001 |
Synonyms | |
Therapy Description |
DUK-CPG-001 act as an agonist of TLR9, resulting in activation of dendritic cells, natural killer cells and B-cells, production of T-helper cells, and induction of immune signaling (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DUK-CPG-001 | TLR9 Agonist 9 | DUK-CPG-001 act as an agonist of TLR9, resulting in activation of dendritic cells, natural killer cells and B-cells, production of T-helper cells, and induction of immune signaling (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02452697 | Phase II | DUK-CPG-001 | Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT | Active, not recruiting | USA | 0 |